AQST-108 (epinephrine) Topical Gel The Company completed its first human clinical study for AQST-108. The two-part study was designed to assess the safety and local tolerability of AQST-108.

May potentiate systemic β-blockers, reserpine, hypoglycemic agents, and mydriatic effects of topical epinephrine. May be potentiated by quinidine.

The LidoSite Topical System consists of a single-use, pre-filled LidoSite Patch, filled with Lidocaine HCl 10% and Epinephrine 0.1%, and the LidoSite Controller, an easy-to-use pre-programmed ...

More than 50 percent of children who were given a topical analgesic had no pain during wound repair with "skin glue," according to the results of a randomized controlled trial reported in CMAJ ...

Interactions May potentiate systemic β-blockers, reserpine, hypoglycemics and mydriatic effect of topical epinephrine. Additive cardiac and pulmonary effects with anticholinesterase miotics.

About AQST-108 AQST-108 (epinephrine) Topical Gel is an epinephrine prodrug topical gel product candidate. Aquestive completed a first in human study for AQST-108 that measured the amount of ...

THE fall in intra-ocular pressure in patients with glaucoma simplex following topical epinephrine therapy has been noted repeatedly1–3. Recent tonographic analysis related this effect primarily ...

Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film Outlines the development ...